Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients

Transfusion

Volumn 52, Issue 10, 2012, Pages 2270-2272

  Nash, Tammon ^a   Hoffmann, Sandra ^b   Butch, Suzanne ^b   Davenport, Robertson ^b   Cooling, Laura ^b  

^a Michigan Blood   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HEALTH CARE POLICY; HUMAN; INSTITUTIONAL CARE; LETTER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT SAFETY; PRESCHOOL CHILD; QUALITY CONTROL; SCHOOL CHILD; STEM CELL TRANSPLANTATION;

ADULT; ANTIBODIES, VIRAL; BLOOD TRANSFUSION; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; LEUKOCYTES; MALE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; UNNECESSARY PROCEDURES;

EID: 84868293041     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03739.x     Document Type: Letter

References (7)

1. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W,. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-603.
2. Smith D, Lu Q, Yuan S, Goldfinger D, Fernando LP, Ziman EA,. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative. Vox Sang 2010; 98: 29-36.
3. Thiele T, Kruger W, Zimmermann K, Ittermann T, Wessel A, Steinmetz I, Kolken G, Greinacher A,. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation. Transfusion 2011; 51: 2620-6.
4. Hoffmann S, Herrst M, Butch S, Cooling L,. Prestorage leukocyte-reduced, CMV untested blood components are safe for use in CMV negative allogeneic bone marrow transplant recipients [abstract]. Transfusion 2007; 47: 212-3.
5. Wu Y, Zou S, Cable R, Korsey K, Tang Y, Hapip CA, Melmed R, Trouern-Trend J, Wang JH, Champion M, Fang C, Dodd R,. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2010; 50: 776-86.
6. Vamvakas EC,. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Tranfus Med Rev 2005; 19: 181-99.
7. Ziemann M, Krueger S, Maier AB, Unmack A, Goerg S, Hennig H,. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007; 47: 1972-83.